Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Neuroectodermal Tumors, Primitive 2Neoplasms 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Hamartoma Syndrome, Multiple 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × dactolisib × Clear all
NCT01290406 2012-06-21

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Novartis

Phase 2 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡